LTRN LTRN
Company Profile ↓Company Overview
LTRN (LTRN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -47.37% |
| 6 Months: | -8.50% |
| 3 Months: | +29.63% |
| 1 Month: | -21.57% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 47.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | - | -833.42K | -1.70M | - | -2.48M | -4.15M | -4.07M | -4.39M | -2.15M | -4.29M | -5.19M | -3.52M | -5.73M | -5.41M | -5.18M | -4.77M | -4.65M | -4.35M | -3.41M |
| Net Income | -629.39K | -669.65K | -477.28K | -833.42K | -1.70M | -2.45M | -2.32M | -4.05M | -4.12M | -4.49M | -2.26M | -3.87M | -4.75M | -3.16M | -5.44M | -4.96M | -4.51M | -4.54M | -4.33M | -4.18M | -3.33M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.41 | -0.21 | -0.36 | -0.44 | -0.29 | -0.51 | -0.46 | -0.42 | -0.42 | -0.40 | -0.39 | -0.30 |
| R&D Expense | - | - | 137.10K | 157.02K | 600.77K | 1.28M | 1.16M | 2.96M | 2.66M | 2.99M | 702.30K | 2.55M | 3.56M | 2.21M | 4.25M | 3.89M | 3.72M | 3.26M | 3.07M | 2.44M | 1.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -12.59M | -14.43M | -17.88M | -22.22M | -17.98M |
| Net Income | -2.43M | -5.91M | -12.36M | -14.26M | -15.96M | -20.78M | -17.12M |
| Diluted EPS | - | - | - | -1.31 | -1.47 | -1.93 | -1.57 |
| R&D Expense | - | 2.24M | 7.57M | 8.60M | 11.89M | 16.13M | 11.51M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.43M | 20.36M | 73.95M | 58.84M | 43.65M | 25.57M | 11.04M |
| Total Equity | -201.80K | 943.28K | 19.70M | 71.57M | 56.04M | 40.91M | 21.19M | 6.53M |
| Cash & Equivalents | 445.16K | 1.23M | 19.23M | 51.52M | 37.20M | 21.94M | 7.51M | 4.42M |
| Total Liabilities | - | 489.29K | 660.84K | 2.38M | 2.80M | 2.74M | 4.38M | 4.50M |
| Current Liabilities | - | 489.29K | 552.34K | 2.33M | 2.80M | 2.68M | 4.33M | 4.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.13M | -5.65M | -10.59M | -12.77M | -14.35M | -17.81M | -15.68M |
| Investing Cash Flow | -5.72K | -16.14K | -19.53M | 179.27K | -930.21K | 3.37M | 11.06M |
| Financing Cash Flow | 2.92M | 23.66M | 63.42M | -2.18M | -500.00K | 66.71K | 1.50M |
| Capital Expenditure | - | - | -15.50K | -27.84K | -18.73K | -12.60K | -1.72K |
| Free Cash Flow | - | - | -10.61M | -12.80M | -14.37M | -17.83M | -15.68M |
| Share Buybacks | - | - | 939.67K | 2.48M | 500.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | -257.4% | -30.0% | -17.3% | -25.4% | -39.0% | -98.1% | -262.0% |
| ROCE % | - | - | -17.6% | -25.8% | -43.6% | -104.6% | -275.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LTRN
New AI company plans to take Lantern Pharma's platform beyond oncology - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPZ0hHaFA1YV9PaGdMZ2Z3d0tOa3ZueG82NHA4TkhSMzFtaktEM1ZESV8wXzNDaTM4aHFXOHNDRmJvTFo1R0NNMDVFRUZNWUtOTklZeHhkSmx6b2ZsYXc2aUI1ZmJpNkZ5d1JWVVVtdWRoSjhzUkJhZkNfMFI2czFGS0dBVWRIbTNITDZHMF…
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOcTV2NGVKeW9LUktTSDlMS1JHWjV5bGtkdGg3Ulc2TzBndmVzNllzb0hGQ005ZVhKc3pTN25zOG5iVV9WOHdGVTY1dDdmanhjY1VFV0ExZDliNVQ3VWxtSVEtc2tYbm8yNXViRnNldERXYlNmcWo5MVY1ZTN2WTF6NFlLZFdqWHM0T2NYWl…
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE0yWldnQXljejZwNk8tcWwzUTZlUXRNVHJoOWphelFxMXhza3pxdnY2MkZlc19pX0F5S0RGVHdxR1pKU2gxazhZR3diTWZmSnh6VndMcFotTDBXbGc?oc=5" target="_blank">LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN)…
LTRN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBCWWtxYTZ3djNpZGpmaTVCQ1pZSEFDT3NpbDEwa1N3TUxjdHctZFVETnA0TzJuRVcxa1MxY3A1VXJVcjlqRjFGbjlTRFBRUXc4UmtKeDVCR195VXhvS25yM1MtMmtnUS0tc183aWFrMUpXOUJkYW82VkhR?oc=5" target="_blank">LTR…
Lantern Pharma (LTRN) Establishes Open-Medicine AI to Expand Mul - GuruFocus
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOQ1J1V05tVnpwSFI5NDdiMDJzSUxXTjhRbDhMYWVUVHFIcUducDRaeV9DRXJ3TzRnMU5wQVpYTEljN2xjQlYzcDZyWnFoREowNDFOSkdpNmRiUFk5ejZXUm1Pbjd6cU5QY2RFaXJkYnA0eW9FZDRhYUtzcWVhcXFUZmg5dnE5VGk0SzM2ak…
LANTERN PHARMA ($LTRN) Releases Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxObm1tSzNPaGtMLVptNk9HRlpYSVpaWW1nTDlHMXBTcUtLa3FIT0hYRDZhUE9KY2FqVE9OT3NrM1pUUC1sVmhnbnVkUWt0cWxMeTUzZ3RiRTAzNXdHNlJzN2VUQ0plcGdWLURHSUVsNXRneUtJUFp6T2RmM2N5S1dsUnptVVM3QTItVUU2bm…
LTRN — Frequently Asked Questions
What is the current share price of LTRN?
As of 2026-08-05 17:25 PDT, LTRN trades at $2.80 on NASDAQ/NYSE. Its 52-week range is $1.12 to $5.32.
What is the P/E ratio of LTRN?
LTRN trades at a trailing price-to-earnings (P/E) ratio of -1.78.
Is LTRN a good stock to buy?
This page provides a data-driven analysis of LTRN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.